Search

Your search keyword '"Récher, Christian"' showing total 889 results

Search Constraints

Start Over You searched for: Author "Récher, Christian" Remove constraint Author: "Récher, Christian"
889 results on '"Récher, Christian"'

Search Results

1. Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration

2. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study

4. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.

7. AML consolidation therapy: timing matters

8. Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia

10. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

11. Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia

12. Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study

14. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO

15. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

16. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

17. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

18. Overlapping features of therapy-related and de novo NPM1-mutated AML

19. Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.

20. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

21. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

22. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

23. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

25. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study

26. Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients.

28. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML

30. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.

32. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia

33. Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia

34. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

35. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

37. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

38. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

39. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort

41. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome

42. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial

44. Genomic landscape of hyperleukocytic acute myeloid leukemia

45. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells

46. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

47. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy

48. Effective interaction in an unbalanced Fermion mixture

49. Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

50. The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France

Catalog

Books, media, physical & digital resources